Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2- deoxy-D-glucose-positron emission tomography imaging biomarkers

Clinical Cancer Research

Volumn 16, Issue 5, 2010, Pages 1542-1552

  Galbán, Craig J ^a   Bhojani, Mahaveer S ^a   Lee, Kuei C ^a   Meyer, Charles R ^a   Van Dort, Marcian E ^a   Kuszpit, Kyle K ^a   Koeppe, Robert A ^a   Ranga, Rajesh ^a   Moffat, Bradford A ^a   Johnson, Timothy D ^a   Chenevert, Thomas L ^a   Rehemtulla, Alnawaz ^a   Ross, Brian D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; DEXAMETHASONE; FLUORODEOXYGLUCOSE F 18;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; GLIOSARCOMA; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; REFERENCE VALUE; STANDARD; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARMUSTINE; DEXAMETHASONE; DIFFUSION MAGNETIC RESONANCE IMAGING; FLUORODEOXYGLUCOSE F18; GLIOSARCOMA; IMAGE PROCESSING, COMPUTER-ASSISTED; INFLAMMATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS;

EID: 77649099103     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1812     Document Type: Article

References (65)

1. Jacobs AH, Kracht LW, Gossmann A, et al. Imaging in neurooncology. NeuroRx 2005;2:333-47.
2. Floyd E, McShane TM. Development and use of biomarkers in oncology drug development. Toxicol Pathol 2004;32 Suppl 1:106-15.
3. Chenevert TL, Meyer CR, Moffat BA, et al. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 2002;1:336-43.
4. Chenevert TL, Sundgren PC, Ross BD. Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am 2006;16: 619-32; viii-ix.
5. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007;25:4104-9.
6. Moffat BA, Hall DE, Stojanovska J, et al. Diffusion imaging for evaluation of tumor therapies in preclinical animal models. Magma 2004; 17:249-59.
7. Brock CS, Young H, O'Reilly SM, et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82:608-15.
8. Castell F, Cook GJ. Quantitative techniques in 18FDG PET scanning in oncology. Br J Cancer 2008;98:1597-601.
9. Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007;48:1468-81.
10. De Witte O, Hildebrand J, Luxen A, Goldman S. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 1994;74:2836-42.
11. Franzius C, Schober O. Assessment of therapy response by FDG PET in pediatric patients. Q J Nucl Med 2003;47:41-5.
12. Lee JK, Liu RS, Shiang HR, Pan DH. Usefulness of semiquantitative FDG-PET in the prediction of brain tumor treatment response to γ knife radiosurgery. J Comput Assist Tomogr 2003;27:525-9.
13. Pan DH, Guo WY, Chung WY, Shiau CY, Liu RS, Lee LS. Early effects of γ Knife surgery on malignant and benign intracranial tumors. Stereotact Funct Neurosurg 1995;64 Suppl 1:19-31.
14. Pardo FS, Aronen HJ, Fitzek M, et al. Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. Anticancer Res 2004;24:2359-65.
15. Spence AM, Muzi M, Krohn KA. Molecular imaging of regional brain tumor biology. J Cell Biochem Suppl 2002;39:25-35.
16. Vlassenko AG, Thiessen B, Beattie BJ, Malkin MG, Blasberg RG. Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI. J Neurooncol 2000;46:249-59.
17. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168:497-505.
18. Szafer A, Zhong J, Gore JC. Theoretical model for water diffusion in tissues. Magn Reson Med 1995;33:697-712.
19. Ross BD, Chenevert TL, Kim B, Ben-Joseph O. Magnetic resonance imaging and spectroscopy: application to experimental neuro-oncology. Q Magn Reson Biol Med 1994;1:89-106.
20. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997;3:1457-66.
21. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36.
22. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000;97:1754-9.
23. Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999;1:113-7.
24. Lee KC, Hall DE, Hoff BA, et al. Dynamic imaging of emerging resistance during cancer therapy. Cancer Res 2006;66:4687-92.
25. Lee KC, Hamstra DA, Bhojani MS, Khan AP, Ross BD, Rehemtulla A. Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res 2007;13:1839-46.
26. Lee KC, Hamstra DA, Bullarayasamudram S, et al. Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther 2006;13:127-37.
27. Lee KC, Moffat BA, Schott AF, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 2007;13:443-50.
28. Lee KC, Sud S, Meyer CR, et al. An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 2007;67:3524-8.
29. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006;8:259-67.
30. Poptani H, Puumalainen AM, Grohn OH, et al. Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 1998;5:101-9.
31. Ross BD, Moffat BA, Lawrence TS, et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003;2:581-7.
32. Schepkin VD, Lee KC, Kuszpit K, et al. Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed 2006;19:1035-42.
33. Stegman LD, Rehemtulla A, Hamstra DA, et al. Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther 2000;7:1005-10.
34. Zhao M, Pipe JG, Bonnett J, Evelhoch JL. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 1996;73:61-4.
35. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005; 102:16759-64.
36. Hayashida Y, Yakushiji T, Awai K, et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results. Eur Radiol 2006;16:2637-43.
37. Hein PA, Kremser C, Judmaier W, et al. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 2003;45:214-22.
38. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2006;17: 505-12.
39. Kremser C, Judmaier W, Hein P, Griebel J, Lukas P, de Vries A. Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging. Strahlenther Onkol 2003;179:641-9.
40. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 2003;21:1094-100.
41. Mardor Y, Roth Y, Lidar Z, et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001;61:4971-3.
42. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524-9.
43. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006;24:843-7.
44. Roth Y, Tichler T, Kostenich G, et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology 2004;232:685-92.
45. Theilmann RJ, Borders R, Trouard TP, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004;6:831-7.
46. Tomura N, Narita K, Izumi J, et al. Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response. J Comput Assist Tomogr 2006;30:496-500.
47. Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008;26:3387-94.
48. Abe Y, Matsuzawa T, Fujiwara T, et al. Assessment of radiotherapeutic effects on experimental tumors using 18F-2-fluoro-2-deoxy-D-glucose. Eur J Nucl Med 1986;12:325-8.
49. Rozental JM, Cohen JD, Mehta MP, Levine RL, Hanson JM, Nickles RJ. Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neurooncol 1993;15:57-66.
50. Rozental JM, Levine RL, Mehta MP, et al. Early changes in tumor metabolism after treatment: the effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1991;20:1053-60.
51. Andersen PB, Blinkenberg M, Lassen U, et al. A prospective PET study of patients with glioblastoma multiforme. Acta Neurol Scand 2006;113:412-8.
52. Ross DA, Sandler HM, Balter JM, Hayman JA, Archer PG, Auer DL. Imaging changes after stereotactic radiosurgery of primary and secondary malignant brain tumors. J Neurooncol 2002;56: 175-81.
53. Waarde AV, Cobben DCP, Suurmeijer AJH, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45:695-700.
54. Yao R, Seidel J, Johnson CA, Daube-Witherspoon ME, Green MV, Carson RE. Performance characteristics of the 3-D OSEM algorithm in the reconstruction of small animal PET images. Ordered-subsets expectation-maximixation. IEEE Trans Med Imaging 2000;19:798-804.
55. Kim B, Boes JL, Frey KA, Meyer CR. Mutual information for automated unwarping of rat brain autoradiographs. Neuroimage 1997;5:31-40.
56. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993; 33:540-8.
57. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumors: is it useful? J Neurol Neurosurg Psychiatry 1995;58:250-52.
58. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for reevaluation of positron emission tomography? Am J Neuroradiol 1998;19:407-13.
59. Wong TZ, Turkington TG, Hawk TC, Coleman RE. PET and brain tumor image fusion. Cancer J 2004;10:234-42.
60. Kaal EC, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol 2004;16:593-600.
61. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 1995; 83:657-64.
62. Mamede M, Saga T, Ishimori T, et al. Differential uptake of (18) F-fluorodeoxyglucose by experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of immunomodification. Neoplasia 2003;5:179-83.
63. Roelcke U, Blasberg RG, von Ammon K, et al. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 1998; 39:879-84.
64. Bastin ME, Carpenter TK, Armitage PA, Sinha S, Wardlaw JM, Whittle IR. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. AJNR Am J Neuroradiol 2006;27:402-8.
65. Hamstra DA, Lee KC, Tychewicz JM, et al. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 2004;10:916-28.